Patient demographics and baseline characteristics18
| STEMI (n=4943) | NSTE-ACS (n=5625) | Total (n=10 568) | |
|---|---|---|---|
| Age, mean (SD) | 59.4 (12.1) | 63.8 (12.1) | 61.8 (12.3) |
| Gender, n (%) | |||
| Male | 3924 (79.4) | 3996 (71.0) | 7920 (74.9) |
| Female | 1019 (20.6) | 1629 (29.0) | 2648 (25.1) |
| Race, n (%) | |||
| Caucasian | 4026 (81.4) | 4784 (85.0) | 8810 (83.4) |
| Black | 19 (0.4) | 38 (0.7) | 57 (0.5) |
| Oriental | 19 (0.4) | 24 (0.4) | 43 (0.4) |
| Unknown | 46 (0.9) | 60 (1.1) | 106 (1.0) |
| Other | 654 (13.2) | 544 (9.7) | 1198 (11.3) |
| BMI, mean (SD)* | 27.5 (4.3) | 28.0 (4.7) | 27.7 (4.5) |
| Region, n (%) | |||
| Northern Europe | 1608 (32.5) | 2174 (38.6) | 3782 (35.8) |
| Southern Europe | 1124 (22.7) | 1213 (21.6) | 2337 (22.1) |
| Eastern Europe | 1145 (23.2) | 1235 (22.0) | 2380 (22.5) |
| Latin America | 1066 (21.6) | 1003 (17.8) | 2069 (19.6) |
| Presence of CV risk factors, n (%) | |||
| Hypertension | 2409 (48.7) | 3709 (65.9) | 6118 (57.9) |
| Hypercholesterolaemia | 1940 (39.2) | 2954 (52.5) | 4894 (46.3) |
| Diabetes mellitus | 893 (18.1) | 1511 (26.9) | 2404 (22.7) |
| Family history of CAD | 1451 (29.4) | 1728 (30.7) | 3179 (30.1) |
| Current smoking | 2204 (44.6) | 1621 (28.8) | 3825 (36.2) |
| Obesity (BMI>30 kg/m2) | 965 (19.5) | 1295 (23.0) | 2260 (21.4) |
| Any previous CVD, n (%) | 1042 (21.1) | 2672 (47.5) | 3714 (35.1) |
| Prior MI | 498 (10.1) | 1462 (26.0) | 1960 (18.5) |
| Prior PCI | 388 (7.8) | 1170 (20.8) | 1558 (14.7) |
| Prior CABG | 84 (1.7) | 534 (9.5) | 618 (5.8) |
| Coronary angiogram diagnostic for CAD | 425 (8.6) | 1475 (26.2) | 1900 (18.0) |
| Chronic angina | 277 (5.6) | 956 (17.0) | 1233 (11.7) |
| Heart failure | 88 (1.8) | 419 (7.4) | 507 (4.8) |
| Atrial fibrillation | 129 (2.6) | 368 (6.5) | 497 (4.7) |
| TIA/stroke | 150 (3.0) | 365 (6.5) | 515 (4.9) |
| Peripheral vascular disease | 145 (2.9) | 384 (6.8) | 529 (5.0) |
| Chronic CV medication in the 3 months prior to index event, n (%) | |||
| Any antiplatelet agent | 1024 (20.7) | 2640 (46.9) | 3664 (34.7) |
| Aspirin | 972 (19.7) | 2476 (44.0) | 3448 (32.6) |
| Clopidogrel | 221 (4.5) | 848 (15.1) | 1069 (10.1) |
| Prasugrel | 13 (0.3) | 16 (0.3) | 29 (0.3) |
| Anticoagulants | 99 (2.0) | 300 (5.3) | 399 (3.8) |
| β-blockers | 833 (16.9) | 2222 (39.5) | 3055 (28.9) |
| ACE inhibitors/ARBs | 1289 (26.1) | 2526 (44.9) | 3815 (36.1) |
| Statins | 900 (18.2) | 2241 (39.8) | 3141 (29.7) |
| Non-statin lipid-lowering agents | 133 (2.7) | 288 (5.1) | 421 (4.0) |
| Aldosterone inhibitors | 50 (1.0) | 174 (3.1) | 224 (2.1) |
| Loop diuretics | 161 (3.3) | 526 (9.4) | 687 (6.5) |
| Non-loop diuretics | 237 (4.8) | 485 (8.6) | 722 (6.8) |
| Calcium channel blocker | 415 (8.4) | 875 (15.6) | 1290 (12.2) |
Reprinted with permission from Bueno et al.18
*BMI was not available for 694 patients with STEMI and 866 patients with NSTE-ACS.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CV, cardiovascular; CVD, CV disease; MI, myocardial infarction; NSTE-ACS, non-ST-segment elevation acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation MI; TIA, transient ischaemic attack.